The Pharma Data

SEPTEMBER 2, 2021

Our presence at ERS this year reiterates our commitment to patients through the further development of first-in-class therapies like Enerzair Breezhaler, as well as by exploring the potential of digital health companions and the carbon footprint of our solutions,” said Dominic Brittain, Respiratory Global Program Head, Novartis Pharmaceuticals.

Licensing 52

Licensing Licensing Treatment Therapies 52

The Pharma Data

NOVEMBER 18, 2020

Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. Department of Hematology and Oncology, Taipei Medical University Hospital, Taipei, Taiwan. current affiliation: Department of Hematology and Oncology, Taipei Tzu Chi Hospital, Taipei, Taiwan. Presenter: Ching-Liang Ho MD, et.al. About OBI Pharma.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

MAY 5, 2022

Novartis today announced the European Commission (EC) has approved Jakavi (ruxolitinib) for the treatment of patients aged 12 years and older with acute or chronic GvHD who have inadequate response to corticosteroids or other systemic therapies. The exact indication for Jakavi varies by country.

Treatment 52

Treatment Disease Therapies Clinical Trials 52

The Pharma Data

OCTOBER 26, 2020

Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. aeruginosa hospital acquired pneumonia cases worldwide.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

NOVEMBER 29, 2020

Y-mAbs Therapeutics has a target action date of November 30 for its Biologics License Application (BLA) for Danyelza (naxitamab) for patients with relapsed/refractory high-risk neuroblastoma. The drug was developed by researchers at Memorial Sloan Kettering Cancer Center and exclusively licensed to Y-mAbs.

FDA 52

FDA Licensing Licensing Pharmaceuticals 52

The Pharma Data

OCTOBER 18, 2020

Dr. Berk most recently has served as a consultant to several companies developing oncology therapies. Berk completed his internship, residency, and fellowship in internal medicine, hematology, and medical oncology at the Weill Cornell Medical College and New York Presbyterian Hospital, where he also served as a faculty member.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

MARCH 4, 2021

Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent ® (dupilumab) as an add-on treatment for children aged 6 to 11 years with uncontrolled moderate-to-severe asthma. Dupixent is approved in the U.S.

FDA 52

FDA Disease Treatment Trials 52

The Pharma Data

JANUARY 13, 2021

Fast Track designation is well-timed, as we anticipate starting our Phase 2 clinical trial in hospitalized COVID-19 patients this month, and should help bring Brilacidin to patients faster in these dire times.”. Brilacidin for UP/UPS was licensed to Alfasigma S.p.A.

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

The Pharma Data

NOVEMBER 25, 2020

With management expertise in hospitality and finance, the Burkhan World Group of Companies, based in Washington D.C. , is an innovative, science-driven pharmaceutical company focused on novel therapies for a variety of indications. is a global investor and partner focused on projects that have a positive impact on society. .

Pharmaceuticals 40

Pharmaceuticals Hospitals Pharmaceutical Companies Licensing 40

The Pharma Data

JANUARY 18, 2021

At the same time, we continue to prepare for the filing of the Biologics License Application with the U.S. million in 2020 despite a very limited access of patients to hospitals due to the COVID-19 crisis. “We Cash position and financing runway. million in the fourth quarter of 2020, and to a total of €5.6 GenSight Biologics S.A.

Treatment 40

Treatment Therapies Clinical Trials Marketing 40

The Pharma Data

MARCH 27, 2022

OLUMIANT, a once-daily, oral JAK inhibitor was discovered by Incyte and licensed to Lilly. Marketing authorization for the treatment of hospitalized patients with COVID-19 has been granted for OLUMIANT in multiple countries. It is approved in the U.S.

Licensing 40

Licensing Licensing Disease FDA Approval 40

The Pharma Data

NOVEMBER 19, 2020

Therapy Selection. Magnis BR, Burning Rock’s fully automated NGS library preparation system, is a key component of Burning Rock’s strategy of empowering hospitals to run NGS tests in-house with minimized lab space and staff requirement. Revenue generated from in-hospital business was RMB31.7 million (US$4.7

Hospitals 52

Hospitals Laboratories Marketing Research 52

The Pharma Data

JANUARY 5, 2021

PWS is an orphan disease with major endocrine and behavioral manifestations and no FDA-approved therapies for the treatment of hyperphagia. medical director of Rady Children’s Hospital multidisciplinary Prader-Willi Syndrome Clinic, said, “Currently, there is no treatment for Prader-Willi syndrome. Disease Highlights. In the U.S.,

Disease 52

Disease FDA Approval Clinical Trials Trials 52

The Pharma Data

OCTOBER 27, 2020

Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has completed the enrollment stage of its NexoBrid ® Phase 3 pediatric clinical study (CIDS – Children Innovation Debridement Study). “We YAVNE, Israel, Oct.

Clinical Trials 40

Clinical Trials Licensing Licensing FDA 40

The Pharma Data

OCTOBER 19, 2020

Pneumococcal serotypes not in the currently licensed conjugate vaccine, such as 22F and 33F, are among the most common serotypes causing invasive pneumococcal disease in parts of the world, including the U.S., among adults 65 years of age or older. About Pneumococcal Disease.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

NOVEMBER 9, 2020

Food and Drug Administration Breakthrough Therapy Designation granted to tezepelumab in Sept. 6-8 Patients with severe asthma account for twice as many asthma-related hospitalizations. Amgen Inflammation Amgen brings therapies to millions of people with inflammatory diseases, with a focus on serving unmet patient needs.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

OCTOBER 29, 2020

. “Our foundation for the future is stronger than ever, and by maintaining our focus on serving patients and delivering for shareholders, I am confident that we will continue to build on our success to date and further advance our mission of delivering life-changing therapies to people with rare diseases and devastating conditions.”

Clinical Trials 40

Clinical Trials Trials Production Licensing 40

The Pharma Data

OCTOBER 28, 2020

REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits). The Phase 3 portion of this trial continues in non-hospitalized patients. combined dose groups; 6.5% placebo; p=0.024).

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

NOVEMBER 9, 2020

We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. Albert Bourla, Pfizer Chairman and CEO. “We About Pfizer: Breakthroughs That Change Patients’ Lives.

Vaccine 40

Vaccine Clinical Trials Trials FDA 40

The Pharma Data

DECEMBER 23, 2020

The lead Principal Investigator for the INNOVATE trial is Dr. Pablo Tebas , Professor of Medicine at the Hospital of the University of Pennsylvania. . About the INO-4800 “INNOVATE” Phase 2/3 Clinical Trial.

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

The Pharma Data

DECEMBER 1, 2020

will reduce the number of people in the high-risk population being hospitalized. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. “The Emergency Use Authorization in the U.K. CEO and Co-founder of BioNTech. “We

Vaccine 40

Vaccine Clinical Trials Trials Production 40

Codon

FEBRUARY 13, 2024

Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Read it on our website here. Illustration by David S. Fast forward to 2023.

Therapies 131

Therapies Virus DNA Clinical Trials 131

The Pharma Data

NOVEMBER 20, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. TARRYTOWN, N.Y., November 21, 2020 – Regeneron Pharmaceuticals, Inc.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

JANUARY 12, 2021

Doses are being supplied for use pursuant to the FDA Emergency Use Authorization for high-risk patients with mild to moderate COVID-19 in order to reduce the risk of progression to severe COVID-19 and/or hospitalization. Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) today announced that the U.S. Yancopoulos , M.D., In the U.S.

Government 52

Government Hospitals Virus Clinical Trials 52

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

APRIL 8, 2021

These important findings advance our pursuit of treatment options to save lives in hospitalized COVID-19 patients.” European Union and other geographies to evaluate next steps for baricitinib for the treatment of hospitalized COVID-19 patients. and 14.7%, respectively) and placebo (44.4% and 18.0%, respectively) groups.

Hospitals 52

Hospitals FDA Approval Laboratories Treatment 52

The Pharma Data

AUGUST 3, 2021

SVP, Chief Medical Officer, Novartis Gene Therapies. “We Additionally, STEER will add to the clinical data and emerging real-world evidence for the use of gene therapy to treat SMA. This route of administration has the potential to open up access for older patients to all the benefits of gene therapy.

Clinical Trials 52

Clinical Trials Trials Therapies Licensing 52

The Pharma Data

APRIL 14, 2021

government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. Bamlanivimab and etesevimab together and bamlanivimab alone are not authorized for use in patients: who are hospitalized due to COVID-19, OR. who require oxygen therapy due to COVID-19, OR. Limitations of Authorized Use.

Government 52

Government Hospitals Long-Term Care Facilities Treatment 52

Codon

JULY 27, 2023

But what happens if you restore these cone cells, using gene therapy? There’s a TV show where a bunch of doctors are walking through a hospital corridor. approved a gene therapy for hemophilia A for the first time. The therapy works by replacing beta-cells with “fresh” cells taken from a, err…dead person.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

But what happens if you restore these cone cells, using gene therapy? There’s a TV show where a bunch of doctors are walking through a hospital corridor. approved a gene therapy for hemophilia A for the first time. The therapy works by replacing beta-cells with “fresh” cells taken from a, err…dead person.

Therapies 52

Therapies RNA DNA Engineering 52

The Pharma Data

APRIL 26, 2022

— Approval is Supported by Phase 2/3 Data Demonstrating the Safety and Tolerability Profile and Clinical Improvement Outcome in Hospitalized Pediatric Patients Treated with Veklury — Gilead Sciences, Inc. At this time, more than half of patients hospitalized with COVID-19 in the United States are treated with Veklury.

Treatment 52

Treatment Hospitals Science Licensing 52

The Pharma Data

NOVEMBER 22, 2020

We believe we are well prepared to press forward given our strong balance sheet and pioneering leadership in the development of muscle-directed therapies.”. We look forward to rapidly advancing next steps for omecamtiv mecarbil , which we expect will include discussions with regulatory authorities. Terms of Termination.

Clinical Trials 52

Clinical Trials Licensing Licensing Trials 52

The Pharma Data

JANUARY 17, 2021

The primary endpoint of the study was composite of time to first occurrence of heart failure hospitalization or cardiovascular death. The study enrolled 5,050 patients who received either vericiguat or placebo in combination with available heart failure therapies. HFrEF was formerly known as systolic heart failure.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

NOVEMBER 21, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. Regeneron Pharmaceuticals, Inc. Food and Drug Administration (FDA).

FDA 40

FDA Clinical Trials Hospitals Production 40

The Pharma Data

MARCH 11, 2021

These new data build upon and confirm previously released data from the MoH demonstrating the vaccine’s effectiveness in preventing symptomatic SARS-CoV-2 infections, COVID-19 cases, hospitalizations, severe and critical hospitalizations, and deaths. variant of SARS-CoV-2 (formerly referred to as the U.K. was the dominant strain.”.

Vaccine 52

Vaccine Clinical Trials Hospitals Licensing 52

The Pharma Data

APRIL 23, 2021

European Commission approves GSK’s JEMPERLI (dostarlimab), the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer. The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe. Dostarlimab was discovered by AnaptysBio and licensed to TESARO, Inc.,

Therapies 40

Therapies Treatment Licensing Licensing 40

The Pharma Data

JULY 8, 2021

Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. Tezepelumab was granted an FDA Breakthrough Therapy Designation for patients with severe asthma without an eosinophilic phenotype in September 2018. About Severe Asthma.

FDA 52

FDA Trials Therapies Treatment 52